Cara Therapeutics, Inc. (CARA) is in free-fall after reporting mixed results. Yet the stock will bottom and bounce back as speculators bottom-fish.Fundamentals are weak. The 1mg, 2.5mg, and 5mg dose results failed to demonstrate joint pain reduction. $CARA, Cara Therapeutics, Inc. / H1 CARA will bottom at $10 a share. Agree or disagree?Login via StockTwits, FB, TWTR to vote now. 'Like' this post.